Ning Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ning Kong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chengcheng Liu
Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an 710061, PR China
1 shared publication - Feiya Xu
Department of Chemistry, School of Science, Xi'an Jiaotong University, Xi'an, 710049, China.
1 shared publication Guanzhi Liu
Department of Bone and Joint Surgery, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publicationHang Yang
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
1 shared publicationHuanshuai Guan
Department of Bone and Joint Surgery, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication- Kunzheng Wang
Department of Bone and Joint Surgery, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication
Latest Publications
- Open Access
- 12 March 2022
- Published by Springer Nature in Bone Research
- Vol. 10 (1) , 1-12
An injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head
Core decompression (CD) with the elimination of osteonecrotic bone is the most common strategy for treating early-stage nontraumatic osteonecrosis of the femoral head (ONFH). Adjuvant treatments are widely used in combination with CD as suitable methods of therapy. Existing augmentations have to be fabricated in advance. Here, we report a novel injectable glycerin-modified polycaprolactone (GPCL) that can adapt to the shape of the CD cavity. GPCL shows great flowability at 52.6 °C. After solidification, its compressive modulus was 120 kPa at body temperature (37 °C). This excellent characteristic enables the polymer to provide mechanical support in vivo. In addition, GPCL acts as a carrier of the therapeutic agent zoledronic acid (ZA), demonstrating sustained release into the CD region. ZA-loaded GPCL was injected into ONFH lesions to treat early-stage nontraumatic cases. Compared to that in the CD group, CD+ZA-loaded GPCL injection preserved bone density and increased the collagen level in the femoral head. At the interface between the GPCL and CD tunnel wall, osteogenesis was significantly promoted. In addition, morphological evaluations revealed that the femoral heads in the CD+ZA-GPCL group exhibited improved pressure resistance. These results suggest a strategy effective to preserve the bone density of the femoral head, thus decreasing the possibility of femoral head collapse. This novel injectable polymer has, therefore, considerable potential in clinical applications.
- 12 March 2022
- Published by Springer Nature in Bone Research
- Vol. 10 (1) , 1-12
Open AccessAn injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head
Core decompression (CD) with the elimination of osteonecrotic bone is the most common strategy for treating early-stage nontraumatic osteonecrosis of the femoral head (ONFH). Adjuvant treatments are widely used in combination with CD as suitable methods of therapy. Existing augmentations have to be fabricated in advance. Here, we report a novel injectable glycerin-modified polycaprolactone (GPCL) that can adapt to the shape of the CD cavity. GPCL shows great flowability at 52.6 °C. After solidification, its compressive modulus was 120 kPa at body temperature (37 °C). This excellent characteristic enables the polymer to provide mechanical support in vivo. In addition, GPCL acts as a carrier of the therapeutic agent zoledronic acid (ZA), demonstrating sustained release into the CD region. ZA-loaded GPCL was injected into ONFH lesions to treat early-stage nontraumatic cases. Compared to that in the CD group, CD+ZA-loaded GPCL injection preserved bone density and increased the collagen level in the femoral head. At the interface between the GPCL and CD tunnel wall, osteogenesis was significantly promoted. In addition, morphological evaluations revealed that the femoral heads in the CD+ZA-GPCL group exhibited improved pressure resistance. These results suggest a strategy effective to preserve the bone density of the femoral head, thus decreasing the possibility of femoral head collapse. This novel injectable polymer has, therefore, considerable potential in clinical applications.
- 3 August 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (68) , 9525-9528
Lanthanide-doped core–shell nanoparticles as a multimodality platform for imaging and photodynamic therapy
We report a novel lanthanide-doped core–shell nanostructure NaYF 4 :Yb,Er@NaGdF 4 :Nd@SiO 2 -RB with a unique design feature that integrates luminescence imaging in biological window II, magnetic resonance imaging, and NIR-excited photodynamic antimicrobial chemotherapy, in a single nanoscale entity.
- 3 August 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (68) , 9525-9528
Lanthanide-doped core–shell nanoparticles as a multimodality platform for imaging and photodynamic therapy
We report a novel lanthanide-doped core–shell nanostructure NaYF 4 :Yb,Er@NaGdF 4 :Nd@SiO 2 -RB with a unique design feature that integrates luminescence imaging in biological window II, magnetic resonance imaging, and NIR-excited photodynamic antimicrobial chemotherapy, in a single nanoscale entity.